Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

MDRNA grants nonexclusive RNA technology rights to Roche

Executive Summary

In the first deal that validates its newly established RNAi drug discovery platform after switching focus from intranasal drug delivery, MDRNA (formerly Nastech) has granted Roche nonexclusive worldwide rights to its siRNA constructs and chemistry platform, which Roche will use to develop RNAi therapeutics.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • R+D and Marketing-Licensing

Related Companies